---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-053288"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2021-11-02T23:59:59+00:00"
generated_at: "2026-06-28T15:28:27.151993+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q3 revenue $810M (+12%), EPS $2.03; raises FY2021 guidance to higher end

## Summary
- Q3 revenue $810M (+12% reported, +10% organic); EPS $2.03 (+20% reported, +12% comparable).
- CAG Diagnostics recurring revenue +13% reported, +11% organic; record Q3 premium instrument placements.
- Updates FY2021 guidance: revenue $3,185-3,200M (17.5-18% growth), EPS $8.30-8.38 (24-25% growth).
- Operating margin 27.9% (+410bps reported, +20bps comparable); benefited from lapping prior year litigation accrual.
- Water revenue +15% reported, +13% organic; LPD revenue declined 21% due to China ASF testing comparison.

## SEC filing metadata
- accession: 0001564590-21-053288
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2021-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000156459021053288/0001564590-21-053288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000156459021053288/idxx-8k_20211102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-053288
- JSON: https://secwatch.observer/filing/0001564590-21-053288.json
- Plain text: https://secwatch.observer/filing/0001564590-21-053288.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.